Description
Retatrutide is an triple-hormone-receptor agonist (targeting GLP-1, GIP, and glucagon receptors) it provides unprecedented weight reduction (up to 24%–28% of body weight), significant blood sugar normalization, marked reductions in liver and visceral fat, and relief from knee osteoarthritis pain.
Core Metabolic and Weight Benefits
- Substantial weight loss: Phase 3 clinical data show average body weight reductions exceeding 26% to 28% over extended trial periods, outperforming traditional single or dual-agonist therapies.
- Enhanced energy expenditure: Unlike older therapies that only curb appetite, the added glucagon receptor activation increases calorie burn and fat oxidation.
- Blood sugar control: Demonstrates strong A1C reductions in type 2 diabetes and helps convert high percentages of prediabetic patients back to normal glycemic levels.
- Deep fat reduction: Clinical observations note dramatic drops in harmful visceral abdominal fat and liver fat infiltration
Reviews
There are no reviews yet.